429 results on '"McFarland, H. F."'
Search Results
2. The Application of Magnetic Resonance Imaging to Phase II Trials in Multiple Sclerosis
3. The Clinical and Social Impact of Interferon-β: The First Approved Therapy in Multiple Sclerosis
4. From specificity to degeneracy to molecular mimicry: antigen recognition of human autoreactive and pathogen-specific CD4+ T cells
5. Antiserums to Neurons and to Oligodendroglia from Mammalian Brain
6. Expression profiling identifies responder and non-responder phenotypes to interferon-β in multiple sclerosis
7. Enhancing Magnetic Resonance Imaging Lesions and Cerebral Atrophy in Patients With Relapsing Multiple Sclerosis
8. Chronic Relapsing Experimental Autoimmune Encephalomyelitis: Effects of Insulin-like Growth Factor-I Treatment on Clinical Deficits, Lesion Severity, Glial Responses, and Blood Brain Barrier Defects
9. DIFFERENTIAL EXPRESSION OF A NOVEL CANDIDATE AUTOANTIGEN, X2 MBP, IN MULTIPLE SCLEROSIS (MS) LESIONS
10. EXPRESSION OF A NOVEL CANDIDATE AUTOANTIGEN, X2 MBP, IN MULTIPLE SCLEROSIS (MS) LESIONS: 214
11. FAILURE OF IMMATURE MICE TO DEVELOP CLINICAL SIGNS OF ACUTE EAE CORRELATES WITH APOPTOTIC CLEARANCE OF LYMPHOCYTES FROM THE CNS: 28
12. Training-dependent plasticity in patients with multiple sclerosis
13. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon
14. Oral interferon beta-1a in relapsing-remitting multiple sclerosis: A double-blind randomized study
15. SELECTIVE NEURONAL, DENDRITIC AND POSTSYNAPTIC LOCALIZATION OF VIRAL ANTIGEN IN MEASLES INFECTED INFECTED MICE
16. Ring and nodular multiple sclerosis lesions: A retrospective natural history study
17. Ethics of placebo-controlled clinical trials in multiple sclerosis: A reassessment
18. A case study on the effect of neutralizing antibodies to interferon beta 1b in multiple sclerosis patients followed for 3 years with monthly imaging
19. Relationship between inflammatory lesions and cerebral atrophy in multiple sclerosis
20. The future of multiple sclerosis therapies: redesigning multiple sclerosis clinical trials in a new therapeutic eraa
21. Interferon-beta-1b effects on re-enhancing lesions in patients with multiple sclerosis
22. MRI as a marker for disease heterogeneity in multiple sclerosis
23. Contrast-enhanced MRI lesions during treatment with interferonβ-1b predict increase in T1 black hole volume in patients with relapsing-remitting multiple sclerosis
24. Interferon- -1b slows progression of atrophy in RRMS: Three-year follow-up in NAb- and NAb+ patients
25. Longitudinal MRI study: The effects of azathioprine in MS patients refractory to interferon -1b
26. Molecular tracking of antigen-specific T cell clones in neurological immune-mediated disorders
27. The role of MRI as a surrogate outcome measure in multiple sclerosis
28. The emerging role of MRI in multiple sclerosis and the new diagnostic criteria
29. Ring-enhancement in multiple sclerosis: marker of disease severity
30. Interferon beta-1b and intravenous methylprednisolone promote lesion recovery in multiple sclerosis
31. The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis
32. Phase 1 trial of transforming growth factor beta 2 in chronic progressive MS
33. Guidelines for using quantitative measures of brain magnetic resonance imaging abnormalities in monitoring the treatment of multiple sclerosis
34. Human T-cell response to myelin basic protein peptide (83-99): Extensive heterogeneity in antigen recognition, function, and phenotype
35. VLA-4 expression on peripheral blood lymphocytes is downregulated after treatment of multiple sclerosis with interferon beta
36. Characterization of MRI response to treatment with interferon beta-1b: Contrast-enhancing MRI lesion frequency as a primary outcome measure
37. Interferon- interferes with the proliferation but not with the cytokine secretion of myelin basic protein-specific, T-helper type 1 lymphocytes
38. Immunodominance of a low-affinity major histocompatibility complex-binding myelin basic protein epitope (residues 111-129) in HLA-DR4 (B1*0401) subjects is associated with a restricted T cell receptor repertoire.
39. Interferon beta results in immediate reduction of contrast-enhanced MRI lesions in multiple sclerosis patients followed by weekly MRI
40. Human autoreactive CD4+ T cell clones use perforin- or Fas/Fas ligand-mediated pathways for target cell lysis.
41. In vitro inhibition of MBP-specific T cell clones by interferon β (IFN-β)
42. Interferon beta results in immediate improvement of contrast-enhanced MRI lesions in multiple sclerosis patients followed by weekly MRI
43. Myelin Basic Protein‐Reactive Human T‐Cell Clones: Stimulation by Diverse Microbial Antigens
44. T‐Cell Receptor α and β CDR3 Expression by Myelin Basic Protein‐Specific Human T‐Cell Clones
45. Two mechanisms of antigen-specific apoptosis of myelin basic protein (MBP)-specific T lymphocytes derived from multiple sclerosis patients and normal individuals.
46. Blood-brain barrier disruption on contrast-enhanced MRI in patients with mild relapsing-remitting multiple sclerosis: Relationship to course, gender, and age
47. HLA restriction and TCR usage of T lymphocytes specific for a novel candidate autoantigen, X2 MBP, in multiple sclerosis.
48. Autoreactive CD8+ T-cell responses to human myelin protein-derived peptides.
49. Significance of autoreactive T cells in diseases such as multiple sclerosis using an innovative primate model.
50. Homologies between T cell receptor junctional sequences unique to multiple sclerosis and T cells mediating experimental allergic encephalomyelitis.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.